Published in Clin Infect Dis on August 01, 2010
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2015) 4.07
Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence (2013) 1.32
Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol (2011) 1.20
Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med (2014) 1.08
Invasive fungal infections in solid organ transplant recipients. Future Microbiol (2012) 1.01
Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect (2015) 1.01
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care (2010) 0.90
Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents (2012) 0.86
Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014. Open Forum Infect Dis (2015) 0.84
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature. Eur J Med Res (2011) 0.83
Invasive candidiasis in non-hematological patients. Mediterr J Hematol Infect Dis (2011) 0.83
Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag (2014) 0.82
Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother (2014) 0.81
Current strategies for the prevention and management of central line-associated bloodstream infections. Infect Drug Resist (2010) 0.80
Use of antifungal drugs in hematology. Rev Bras Hematol Hemoter (2012) 0.79
Catheter-related Candida bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study. BMC Infect Dis (2014) 0.79
Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species. Antimicrob Agents Chemother (2016) 0.78
Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis (2015) 0.77
Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment? Indian J Hematol Blood Transfus (2014) 0.76
Should the guidelines for management of central venous catheters in patients with candidemia be changed now? Clin Infect Dis (2010) 0.76
Candida infections among neutropenic patients. Caspian J Intern Med (2016) 0.75
The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia. Antibiotics (Basel) (2014) 0.75
Diagnostic usefulness of differential time to positivity for catheter-related candidemia. J Clin Microbiol (2014) 0.75
Early removal of central venous catheters and outcomes from candidemia. Clin Infect Dis (2010) 0.75
Catheter extraction does not improve survival in candidemia, or does it? Clin Infect Dis (2010) 0.75
Antifungal clinical trials and guidelines: what we know and do not know. Cold Spring Harb Perspect Med (2014) 0.75
Epidemiology and mortality of candidemia both related and unrelated to the central venous catheter: a retrospective cohort study. Eur J Clin Microbiol Infect Dis (2016) 0.75
Candida species bloodstream infections in hospitalised children: A 10-year experience. J Paediatr Child Health (2015) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
The molecular classification of multiple myeloma. Blood (2006) 8.77
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis (2007) 4.23
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Fusarium infections in immunocompromised patients. Clin Microbiol Rev (2007) 3.44
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med (2012) 2.55
Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics (2008) 2.51
Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis (2002) 2.44
Treatment of multiple myeloma. Blood (2003) 2.34
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr (2007) 2.32
Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis (2009) 2.27
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N Engl J Med (2012) 2.25
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis (2002) 2.20
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis (2010) 2.10
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood (2006) 2.06
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol (2006) 1.96
Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis (2002) 1.85
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother (2002) 1.79
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A (2010) 1.78
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol (2011) 1.76
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis (2003) 1.74
Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood (2009) 1.74
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood (2005) 1.71
Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis (2011) 1.70
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol (2010) 1.66
Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis (2007) 1.63
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother (2005) 1.59
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis (2011) 1.56
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood (2009) 1.56
Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis (2004) 1.55
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol (2002) 1.54
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol (2002) 1.54
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res (2007) 1.53
Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect (2013) 1.52
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol (2009) 1.51
Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis (2012) 1.47
Human listeriosis caused by Listeria ivanovii. Emerg Infect Dis (2010) 1.46
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw (2008) 1.46
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol (2006) 1.44
Persistent culture-positive Legionella infection in an immunocompromised host. Clin Infect Dis (2005) 1.43
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Healthcare-associated mucormycosis. Clin Infect Dis (2012) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect (2006) 1.38
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer (2008) 1.38
The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J (2006) 1.36
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.34
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 1.31
Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am (2010) 1.29
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer (2007) 1.29
Molecular identification of black-grain mycetoma agents. J Clin Microbiol (2006) 1.28
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol (2007) 1.28
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother (2007) 1.28